L-AP4 je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist koji je selektivan za grupu III metabotropnih glutamatnih receptora (mGluR4/6/7/8). On je bio privi ligand za koji je utvrđeno da deluje kao selektivni agonist za ovu grupu mGlu receptora.[3] On se koristi u izučavanju ove receptorske familije i njihovih funkcija.[4][5][6][7]
Kratke činjenice (IUPAC) ime, Klinički podaci ...
Zatvori
Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Thomsen C (1997). „The L-AP4 receptor”. General pharmacology 29 (2): 151–8. PMID 9251893.
Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M (2007). „Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease”. Journal of Neuroscience 27 (25): 6701–11. DOI:10.1523/JNEUROSCI.0299-07.2007. PMID 17581957.
MacInnes N, Duty S (2008). „Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo”. European journal of pharmacology 580 (1–2): 95–9. DOI:10.1016/j.ejphar.2007.10.030. PMID 18035348.
MacIejak P, Szyndler J, Turzyńska D, Sobolewska A, Taracha E, Skórzewska A, Lehner M, Bidziński A, Hamed A (2009). „The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration”. Brain research 1282: 20–7. DOI:10.1016/j.brainres.2009.05.049. PMID 19481536.
|
Portal Medicina |
|
Portal Hemija |